Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
43 hedge funds and large institutions have $191M invested in Surface Oncology, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 9 closing their positions.
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 47 → 43 (-4)
33% less capital invested
Capital invested by funds: $285M → $191M (-$94.1M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.26M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.58M |
| 4 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$1.28M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.91M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.95M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.63M |
| 4 |
OA
Omega Advisors
New York
|
-$1.55M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$627K |
SURF Hedge Fund Activity: Q3 2018 in Review
43 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q3 2018, worth a combined $191M — down 33% from $285M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SURF and 5 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 22 added.
The largest buyer was EcoR1 Capital, adding an estimated $5.54M. The largest seller was Fidelity Investments, cutting an estimated $7.91M.
- 43 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q3 2018, down from 47 in Q2 2018.
- Funds reported $191M of Surface Oncology, Inc. Common Stock stock for Q3 2018, down 33% quarter-over-quarter.
- 5 funds opened new Surface Oncology, Inc. Common Stock positions in Q3 2018 and 9 closed out, a net change of -4 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q3 2018 was EcoR1 Capital, an estimated $5.54M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q3 2018 was Fidelity Investments, an estimated $7.91M sold.
Based on aggregated 13F filings for Q3 2018.